KRAS/NRAS and BRAF Mutations in the 20050181 Study of Panitumumab + FOLFIRI for the 2ND-Line Treatment of Metastatic Colorectal Cancer: Updated Analysis
Marc Peeters(Ghent University Hospital), Scott D. Patterson(Amgen (United States)), Yevhen Hotko(Ghent University Hospital), Cornelis J.A. Punt(University of Amsterdam), Kelly S. Oliner(Ghent University Hospital), Florian Lordick(Leipzig University), G. Wilson(Ghent University Hospital), Timothy Price, Laslo Roman(Ghent University Hospital), Thierry André(Sorbonne Université), Michel Ducreux(Université Paris-Saclay), Emily Chan(Royal Marsden NHS Foundation Trust), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Alberto F. Sobrero(Ospedale Policlinico San Martino), Andrés Cervantes(Universitat de València), Hua Yu(Amgen (United States)), A. H. Strickland(Monash Medical Centre), Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta), R. Sidhu(McMaster University), A. Scott Jung(Amgen (United States))
Cited by 3
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Gastric cancer
|The Lancet|2020|4.8k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k